PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment

Angel Guerrero-Zotano, Ingrid A. Mayer, Carlos L. Arteaga

Research output: Contribution to journalArticlepeer-review

289 Scopus citations


Anti-cancer cancer-targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Mutations in the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway are freqcuently found in breast cancers and associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK/mTOR are currently in clinical trials, mainly in combination with endocrine therapy and anti-HER2 therapy. These drugs are the focus of this review.

Original languageEnglish (US)
Pages (from-to)515-524
Number of pages10
JournalCancer and Metastasis Reviews
Issue number4
StatePublished - Dec 1 2016


  • AKT
  • Breast cancer
  • mTOR
  • PI3K

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment'. Together they form a unique fingerprint.

Cite this